ZYNE Stock Overview
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 1 more risk
My Notes
NewNotes are coming soon
Zynerba Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.61 |
| 52 Week High | US$2.94 |
| 52 Week Low | US$0.49 |
| Beta | 1.72 |
| 1 Month Change | 12.55% |
| 3 Month Change | -6.48% |
| 1 Year Change | -77.90% |
| 3 Year Change | -87.87% |
| 5 Year Change | -94.66% |
| Change since IPO | -96.25% |
Recent News & Updates
Recent updates
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?
Nov 11
Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome
Oct 06Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01
Aug 10We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth
Jul 22Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital
Jul 21Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation
Mar 23We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth
Dec 02We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth
May 27Zynerba Pharma shares slip 10% on Zygel update in Fragile X syndrome
Dec 17Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?
Nov 23
Zynerba Pharmaceuticals EPS beats by $0.12
Nov 09Zynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite Setback
Oct 29Shareholder Returns
| ZYNE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -9.0% | -0.7% | 0.9% |
| 1Y | -77.9% | 4.9% | -10.9% |
Return vs Industry: ZYNE underperformed the US Pharmaceuticals industry which returned 4.9% over the past year.
Return vs Market: ZYNE underperformed the US Market which returned -10.9% over the past year.
Price Volatility
| ZYNE volatility | |
|---|---|
| ZYNE Average Weekly Movement | 11.1% |
| Pharmaceuticals Industry Average Movement | 11.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ZYNE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: ZYNE's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 28 | Armando Anido | https://www.zynerba.com |
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery.
Zynerba Pharmaceuticals, Inc. Fundamentals Summary
| ZYNE fundamental statistics | |
|---|---|
| Market Cap | US$27.42m |
| Earnings (TTM) | -US$35.83m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs ZYNE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZYNE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$35.83m |
| Earnings | -US$35.83m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.80 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ZYNE perform over the long term?
See historical performance and comparison